Ann
Etase activity in cerebrospinal fluid of Alzheimer’s disease subjects. Ann Neurol 2004, 55(6):898?99. 100. Colciaghi F, Borroni B, Pastorino L, Marcello E, Zimmermann M, Cattabeni F, Padovani A, Di Luca M: [alpha]-Secretase ADAM10 as well as [alpha]APPs is reduced in platelets and CSF of Alzheimer disease patients. Mol Med 2002, 8(2):67?4. 101. Colciaghi F, Marcello E, Borroni B, Zimmermann M, Caltagirone C, Cattabeni F, Padovani A, Di Luca M, Platelet APP: ADAM 10 and BACE alterations in the early stages of Alzheimer disease. Neurology 2004, 62(3):498?01.102. Tang K, Hynan LS, Baskin F, Rosenberg RN: Platelet amyloid precursor protein processing: a bio-marker for Alzheimer’s disease. J Neurol Sci 2006, 240(1?):53?8. 103. Zubenko GS, Cohen BM, Boller F, Malinakova I, Keefe N, Chojnacki B: Platelet membrane abnormality in Alzheimer’s disease. Ann Neurol 1987, 22(2):237?44. 104. Zubenko GS, Brenner RP, Teply I: Risk factors for stroke as predictors of platelet membrane fluidity in Alzheimer’s disease. Stroke 1991, 22(8): 997?003. 105. Hajimohammadreza I, Brammer MJ, Eagger S, Burns A, Levy R: Platelet and erythrocyte membrane changes in Alzheimer’s disease. Biochim Biophys Acta 1990, 1025(2):208?14. 106. Kanof PD, Mohs RC, Gross J, Davidson M, Bierer LM, Davis KL: Platelet phospholipid synthesis in Alzheimer’s disease. Neurobiol Aging 1991, 12(1):65?9. 107. Piletz JE, Sarasua M, Whitehouse P, Chotani M: Intracellular membranes are more fluid in platelets of Alzheimer’s PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/20618955 disease patients. Neurobiol Aging 1991, 12(5):401?06. 108. Cohen BM, Zubenko GS, Babb SM: Abnormal platelet membrane composition in Alzheimer’s-type dementia. Life Sci 1987, 40(25): 2445?451. 109. Liu WW, Todd S, Coulson DT, Irvine GB, Passmore AP, McGuinness Fmoc-D-Asp-OtBu B, McConville M, Craig D, Johnston JA: A novel reciprocal and biphasic relationship between membrane cholesterol and beta-secretase activity in SH-SY5Y cells and in human platelets. J Neurochem 2009, 108(2): 341?49. 110. Grimm MO, PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/14704548 Grimm HS, P zold AJ, Zinser EG, Halonen R, Duering M, Tsch e JA, De Strooper B, 1-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole M ler U, Shen J, Hartmann T: Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat Cell Biol 2005, 7(11):1118?123. 111. Shimohama S, Fujimoto S, Matsushima H, Takenawa T, Taniguchi T, Perry G, Whitehouse PJ, Kimura J: Alteration of phospholipase C-delta protein level and specific activity in Alzheimer’s disease. J Neurochem 1995, 64 (6):2629?634. 112. Matsushima H, Shimohama S, Fujimoto S, Takenawa T, Kimura J: Reduction of platelet phospholipase C activity in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 1995, 9(4):213?17. 113. Matsushima H, Shimohama S, Kawamata J, Fujimoto S, Takenawa T, 1-Dicyclopropylmethanamine hydrochloride Tris(dibenzylideneacetonyl)bis-palladium NH2-C5-NH-Boc Chromane-2-carboxylic acid 2-Methylpyrimidine-5-carboxylic acid 4-(Trifluoromethyl)-1H-pyrazole (3-Bromopyridin-2-yl)methanol Methyl (4-cyanophenyl)acetate Myosmine 1-Bromo-2-(bromomethyl)-4 Kimura J: Reduction of platelet phospholipase C-delta1 activity in Alzheimer’s disease associated with a specific apolipoprotein E genotype (epsilon3/ epsilon3). Int J Mol Med 1998, 1(1):91?3. 114. Balsinde J, Balboa MA, Insel PA, Dennis EA: Regulation and inhibition of phospholipase A2. Annu Rev Pharmacol Toxicol 1999, 39:175?89. Review. 115. Emmerling MR, Moore CJ, Doyle PD, Carroll RT, Davis RE: Phospholipase A2 activation influences the processing and secretion of the amyloid precursor protein. Biochem Biophys Res Commun 1993, 197(1):292?97. 116. Lehtonen JY, Holopainen JM, Kinnunen PK: Activation of phospholipase A2 by amyloid beta-peptides in vitro. Biochemistry 1996, 35(29):9407?414. 117. Krzystanek E, Krzystanek M, Opala G, Trzeciak HI, Siuda J, Malecki A: Platelet phos.